Creating value with biosimilars

Through our biosimilar development projects, Formycon creates not only highly effective, more affordable biologic drugs for patients but also long-term value for its investors. Biosimilars are a new class of medicines with a very promising future, and our product candidates are targeted at multi-billion-dollar markets.

Formycon AG share chart

Shareholder structure

43% family offices
27% free float
23% institutional investors
   7% founders and management

Legal form

German stock corporation (Aktiengesellschaft)

Initial exchange listing

December 20, 2010





Exchange and market segment

Frankfurt Stock Exchange “Scale” Segment (Open Market)

Share type

Bearer shares without par value

Registered capital

EUR 15,128,775.00

Shares outstanding

15,128,775 bearer shares

Capital Market Partner

Wolfgang Steubing AG

Designated Sponsors

Wolfgang Steubing AG
mwb fairtrade Wertpapierhandelsbank AG

as of September 2022